(R)-Carteolol is an enantiomer of the drug carteolol that is used to treat glaucoma. (R)-Carteolol is a partial agonist with the high affinity to the beta-adrenoceptors. It was shown, that in the treatment of glaucoma, the therapeutic advantage of the R(+)-isomers is similar to the S(-)-isomers and there is no stereoselectivity between the two enantiomers.

Carteolol is a nonselective beta-adrenoceptor blocking agent for ophthalmic use. It has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications. The following adverse reactions have been reported: transient eye irritation, burning, tearing, conjunctival hyperemia and edema. Carteolol may cause bradycardia and decreased blood pressure, headache, arrhythmia, syncope, heart block, cerebral vascular accident, cerebral ischemia, congestive heart failure, palpitation, nausea, depression. Carteolol should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade.

(R)-Carteolol is an enantiomer of the drug carteolol that is used to treat glaucoma. (R)-Carteolol is a partial agonist with the high affinity to the beta-adrenoceptors. It was shown, that in the treatment of glaucoma, the therapeutic advantage of the R(+)-isomers is similar to the S(-)-isomers and there is no stereoselectivity between the two enantiomers.

(S)-Carteolol is an enantiomer of the racemic drug carteolol, that is used to treat glaucoma. (S) isomer is a partial agonist with the high affinity to the beta-adrenoceptors. It was shown, that in the treatment of glaucoma, the therapeutic advantage of the R(+)-isomers is similar to the S(-)-isomers and there is no stereo-selectivity between the two enantiomers.